Jasper Therapeutics (JSPR) Company Report

Jasper Therapeutics (JSPR) announced positive updated data for briquilimab in chronic spontaneous urticaria (CSU) from its BEACON and open-label extension studies on January 8, 2026.
In the BEACON study, five of six patients achieved a complete response by week three, with four of six achieving a complete response at week 12. The open-label extension study showed 62% of CSU patients achieved a complete response at week 20.
The company plans to initiate a Phase 2b study for briquilimab in CSU in the second half of 2026, designed as an operationally adaptive Phase 2b/3 trial with 75 to 100 adult patients.
Jeet Mahal has been appointed as the new CEO.
The company's current capital is expected to fund operations through the middle of 2026 and into the third quarter of 2026, indicating a future need to raise capital.

Jan 8, 2026, 1:00 PM

Transcript

Jasper Therapeutics provides chronic urticaria data update and announces CEO change

JSPR

CEO Change

New Projects/Investments

Jasper Therapeutics presented updated data from its BEACON study and open-label extension study for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) on January 8, 2026, highlighting briquilimab's rapid onset of disease control, durable efficacy, and favorable safety profile.
In the BEACON study's Cohort 9.1, five of six patients achieved a complete response by week three, with four of six achieving a complete response at week 12. The CSU portion of the open-label extension showed 62% of patients achieving a complete response at week 20.
Briquilimab demonstrated a favorable chronic safety profile with low incidence of KIT-related adverse events, which were generally low-grade, mostly resolved during repeat dosing, and did not lead to discontinuations in Cohort 9.1.
The company plans to commence a Phase 2b study for CSU, expected to start in the second half of 2026, involving approximately 75 to 100 adult patients to evaluate two dose regimens versus placebo.
Jeet Mahal was promoted to CEO, replacing Ron Martell, a decision made by the board to align with the company's development stage and future leadership needs.

Jan 8, 2026, 1:00 PM

Transcript

Jasper Therapeutics provides update on chronic urticaria data and announces CEO change

JSPR

CEO Change

New Projects/Investments

Guidance Update

Jasper Therapeutics reported updated data from its BEACON study and open-label extension study for briquilimab in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), demonstrating rapid onset of disease control, durable efficacy, and a favorable safety profile for chronic dosing.
In the BEACON study's Cohort 9.1, five of six patients achieved a complete response by week three, with four of six maintaining a complete response at week 12. The open-label extension study showed 62% of CSU patients achieving a complete response at week 20.
The company plans to initiate a Phase 2b study for CSU, enrolling 75 to 100 adult patients, in the second half of 2026. This study will evaluate two dose regimens against placebo and is designed as an operationally adaptive Phase 2b/3 trial.
Jeet Mahal has been appointed as the new CEO, succeeding Ron Martell, with the board citing the company's development stage and future leadership needs as the rationale.
Current capital is projected to fund operations through the middle of 2026 and into the third quarter of 2026, indicating an upcoming need for additional financing.

Jan 8, 2026, 1:00 PM

Transcript

Jasper Therapeutics Reports Favorable Briquilimab Efficacy and Safety Data

JSPR

New Projects/Investments

Jasper Therapeutics announced positive BEACON and Open-Label Extension (OLE) study results for Briquilimab, an investigative drug for Chronic Spontaneous Urticaria (CSU).
Briquilimab demonstrated rapid and durable clinical responses, with 83% of patients in BEACON Cohort 9.1 achieving a complete response (CR) by week 3, and 67% CRs at 12 weeks.
The drug was well tolerated with a favorable safety profile, showing low incidence of KIT-related adverse events that were predominantly low grade and transient.
These data support advancing Briquilimab into a Phase 2b CSU study in the second half of 2026.

Jan 8, 2026, 1:00 PM

Presentation

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies

JSPR

New Projects/Investments

Jasper Therapeutics (JSPR) reported positive updated clinical data from its BEACON Phase 1b/2a study and open-label extension study of subcutaneous briquilimab for Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU).
In the BEACON study, 67% of additional patients (n=6) achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points.
The open-label extension study demonstrated that 75% of CSU participants (n=36) achieved a complete response or well-controlled disease at 12 weeks.
Briquilimab exhibited a favorable safety and tolerability profile in both studies, with KIT-related adverse events being low-grade and resolving during the study.
These data are sufficient to enable dose selection for a Phase 2b study in CSU, which is planned to commence in the second half of 2026.

Jan 8, 2026, 12:06 PM

8-K

Jasper Therapeutics Reports Positive Updated Briquilimab Data for Chronic Urticaria Studies

JSPR

Product Launch

New Projects/Investments

Jasper Therapeutics announced positive updated clinical data for briquilimab from its BEACON Phase 1b/2a study and open-label extension study in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU).
In the BEACON study, 67% of additional patients (n=6) achieved a complete response at 12 weeks, with 83% achieving it by week 3.
The open-label extension study demonstrated 75% of CSU participants (n=36) achieved a complete response or well-controlled disease at 12 weeks, with briquilimab being well-tolerated over a median follow-up of 205 days in 63 patients.
The company confirmed that the collected data is sufficient for dose selection for a Phase 2b study of briquilimab in CSU, expected to commence in the second half of 2026.

Jan 8, 2026, 12:00 PM

Press Release

JJP Biologics Announces Positive Phase I Trial Results for JJP-1212

JSPR

New Projects/Investments

Guidance Update

JJP Biologics announced positive top-line results from its Phase I clinical trial of JJP-1212, a potential first-in-class anti-CD89 antagonist developed for autoimmune, inflammatory, and fibrotic diseases.
The trial successfully met all primary endpoints, demonstrating a favorable safety and tolerability profile for JJP-1212, with no dose-limiting toxicities observed and adverse events reported as mild-to-moderate.
The company plans to report results from its Phase 1b trial in Linear IgA Disease in Q1 2026 and initiate a broad clinical program of Phase 2 trials by Q3 2026.

Jan 7, 2026, 6:00 AM

Press Release

Jasper Therapeutics provides clinical trial updates and cash runway guidance

JSPR

Guidance Update

New Projects/Investments

Jasper Therapeutics concluded an internal investigation into unexpected results in the Beacon study for chronic spontaneous Urticaria (CSU), determining that 9 of 10 patients were misdiagnosed and did not have mast cell mediated CSU, while the drug product was found to be effective. New patient screening measures have been implemented for future enrollments.
The company expects to release the next significant data from the Beacon study, including new patients in cohorts 8 and 9 and longer-term safety follow-up from the Open Label Extension (OLE), in the first half of Q1 2026.
Positive data from an allergen challenge study in asthma showed a major reduction in Eosinophils in sputum at 6 and 12 weeks following a single dose of Briquilimab.
Jasper Therapeutics' cash runway extends into the middle of Q3 2026, following a recent $30 million capital raise. This capital is sufficient to initiate the planned Phase II-B study for CSU, which is estimated to cost $40-$50 million, but not to conduct it fully.

Dec 3, 2025, 8:00 PM

Transcript

Jasper Therapeutics Provides Update on Briquilimab Clinical Programs and Cash Runway

JSPR

Guidance Update

New Projects/Investments

Jasper Therapeutics' lead program, briquilimab (BRIC), is in clinical development for chronic spontaneous urticaria (CSU), inducible urticaria, and asthma.
An internal investigation into unexpected results in CSU cohorts 8 and 9 concluded that 9 of 10 patients were misdiagnosed with mast cell mediated CSU, not due to an issue with the drug product. New patient screening measures are being implemented for future CSU studies.
Key catalysts include the next data milestone for the CSU Beacon study, expected in the first half of Q1 2026, which will provide data on new patients in cohorts 8 and 9 and longer-term safety from the Open Label Extension.
In an asthma allergen challenge study, briquilimab treatment resulted in a major reduction in eosinophils in sputum at six and 12 weeks.
The company has a cash runway into Q3 2026 following a recent $30 million capital raise, which will fund the initiation of the planned CSU Phase 2b study but not its full conduct.

Dec 3, 2025, 8:00 PM

Transcript

Jasper Therapeutics Provides Briquilimab Clinical Trial Updates and Cash Runway

JSPR

New Projects/Investments

Guidance Update

An internal investigation into unexpected results in the Beacon study for chronic spontaneous urticaria (CSU) concluded that 9 of 10 patients in cohorts 8 and 9 were misdiagnosed and did not have mast cell mediated CSU, confirming the drug product's efficacy.
The next data milestone for the Beacon study is expected in the first half of Q1 (next year), including new patient data from cohorts 8 and 9 and longer-term safety data from the Open Label Extension (OLE). An efficacy response rate around 50% would be considered a success.
In the asthma allergen challenge study, briquilimab demonstrated a major reduction in eosinophils in sputum at 6 and 12 weeks, despite the study being halted early due to initial concerns about the drug lot.
Jasper Therapeutics has a cash runway into the middle of next year (Q3), supported by a recent $30 million capital raise, which is sufficient to initiate but not fully conduct the Phase 2B study.